Physician profile
David M Lam
NPI 1174996342
$1,525.34
in general payments reported to CMS, 2019-2025
18 companies · $331 in 2025
The $331 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.31 · 2020: $103 · 2021: $69.56 · 2022: $110 · 2023: $358 · 2024: $460 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,148.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $257.20 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $204.43 | 2023-2024 | Lifevest |
| Recordati_rare_diseases_inc. | $168.89 | 2024-2025 | Isturisa, Signifor Lar |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $159.96 | 2019-2020 | |
| Lilly USA, LLC | $133.48 | 2023-2024 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.07 | 2022-2025 | Jardiance |
| Novo Nordisk INC | $99.11 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $96.17 | 2020-2025 | Eterna, Freestyle Libre 3 |
| Insulet Corporation | $87.59 | 2022-2024 | Omnipod |
| Dexcom, INC. | $34.81 | 2021-2025 | Dexcom G6 Transmitter |
| Mannkind Corporation | $26.82 | 2025 | |
| Sumitomo Pharma America, INC. | $26.58 | 2024 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $24.56 | 2023 | Gvoke Hypopen |
| Corcept Therapeutics | $19.76 | 2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $17.33 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $16.19 | 2024 | Tepezza |
| Tandem Diabetes Care, INC. | $15.62 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Organon LLC | $7.77 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.